China Pharma Holdings Inc (CPHI) concluded trading on Thursday at a closing price of $1.50, with 0.49 million shares of worth about $0.74 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -36.18% during that period and on April 17, 2025 the price saw a loss of about -4.06%. Currently the company’s common shares owned by public are about 3.26M shares, out of which, N/A shares are available for trading.
Stock saw a price change of 9.64% in past 5 days and over the past one month there was a price change of -46.70%. Year-to-date (YTD), CPHI shares are showing a performance of -35.63% which decreased to -54.96% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.20 but also hit the highest price of $4.10 during that period. The average intraday trading volume for China Pharma Holdings Inc shares is 90.91K. The stock is currently trading -26.33% below its 20-day simple moving average (SMA20), while that difference is down -31.40% for SMA50 and it goes to -31.44% lower than SMA200.
China Pharma Holdings Inc (AMEX: CPHI) currently have 3.26M outstanding shares and institutions hold larger chunk of about 0.53% of that.
The stock has a current market capitalization of $4.88M and its 3Y-monthly beta is at 1.00. It has posted earnings per share of -$2.73 in the same period. It has Quick Ratio of 0.20 while making debt-to-equity ratio of 0.45. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CPHI, volatility over the week remained 23.52% while standing at 18.63% over the month.
Analysts are in expectations that China Pharma Holdings Inc (CPHI) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on January 08, 2010 offering a Mkt outperform rating for the stock and assigned a target price of $6 to it.
